|Lehti||Clinical and Experimental Rheumatology|
|DOI - pysyväislinkit|
|Tila||Julkaistu - heinäk. 2022|
|OKM-julkaisutyyppi||A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu|
M. Schrumpf Heiberg has received speakers honoraria from Lilly and Roche over the last four years, but none of them unrelated to this work. E.A. Haavardsholm has received grants from the Norwegian Regional Health Authorities and The South-Eastern Norway Regional Health Authority during the conduct of the NORD-STAR study, and speaker and/or consulting fees from Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli-Lilly and UCB unrelated to this work. D. Nordström has received consulting fees from AbbVie, BMS, Lilly, MSD, Novartis, Roche, Pfizer and UCB. B. Gudbjornsson has received speaking fees from Novartis and Amgen unrelat ed to this work. R. van Vollenhoven reports receiving institutional grants from BMS, GSK, Lilly, Pfizer, Roche and UCB for re search and educational programmes, consulting and/or speaking fees from AbbVie, AstraZeneca, Biogen, Biotest, BMS, Galapagos, Gilead, GSK, Jans- sen, Pfizer, Sanofi, Servier, UCB and Vielabio, all unrelated to this work. The other authors have declared no competing interests.
M. Lund Hetland has received research grants from Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Bioepis, Sandoz, Novartis, chairs the steering committee of the Danish Rheumatology Quality Registry (DANBIO), which receives public funding from the hospital owners and funding from pharmaceutical companies and co-chairs EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondyloarthritis based on secondary-data and is partly funded by Novartis. M. Østergaard has received research grants from Abbvie, BMS, Merck, Celgene and Novartis, and speaker and/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regen-eron, Roche, Sandoz, Sanofi and UCB.
Funding: this study was supported by grants from Swedish Research Council (#2019-01035), King Gustaf V’s 80-year foundation (no. FAI-2019-0603) and the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (no. ALFGBG-717541). Funding for the Swedish part of the NORD-STAR study was provided by Stockholm County Council, Sweden (grant no. 20100490), the Swedish Medical Research Council (grant no. C0634901, D0342301, 201500891_5) and the Swedish Rheumatism Association. Competing interests: page 1401.
© Copyright Clinical and Experimental Rheumatology 2022.
- 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet